The effectiveness of the Guy’s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients
-
Published:2021-01-05
Issue:6
Volume:124
Page:1079-1087
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Dolly Saoirse OliviaORCID, Jones Geraint, Allchorne Paula, Wheeler Daniel, Ali Sunnyath, Mukadam Yaseen, Zheng Sifan, Rahman Loay, Sindhar Jan, Moss Charlotte Louise, Harari Danielle, Van Hemelrijck Mieke, Cunliffe Anthony, De Michele Luigi Vincenzo
Abstract
Abstract
Background
Rapid Diagnostic Clinics (RDC) are being expanded nationally by NHS England. Guy’s RDC established a pathway for GPs and internal referrals for patients with symptoms concerning for malignancy not suitable for a site-specific 2WW referral. However, little data assessing the effectiveness of RDC models are available in an English population.
Methods
We evaluated all patients referred to Guy’s RDC between December 2016 and June 2019 (n = 1341) to assess the rate of cancer diagnoses, frequency of benign conditions and effectiveness of the service.
Results
There were 96 new cancer diagnoses (7.2%): lung (16%), haematological (13%) and colorectal (12%)—with stage IV being most frequent (40%). Median time to definitive cancer diagnosis was 28 days (IQR 15–47) and treatment 56 days (IQR 32–84). In all, 75% were suitable for treatment: surgery (26%), systemic (24%) and radiotherapy (14%). Over 180 serious non-neoplastic conditions were diagnosed (35.8%) of patients with no significant findings in two-third of patients (57.0%).
Conclusions
RDCs provide GPs with a streamlined pathway for patients with complex non-site-specific symptoms that can be challenging for primary care. The 7% rate of cancer diagnosis exceeds many 2WW pathways and a third of patients presented with significant non-cancer diagnoses, which justifies the need for rapid diagnostics. Rapid Diagnostic Centres (RDCs) are being rolled out nationally by NHS England and NHS Improvement as part of the NHS long-term plan. The aim is for a primary care referral pathway that streamlines diagnostics, patient journey, clinical outcomes and patient experience. This pilot study of 1341 patients provides an in-depth analysis of the largest single RDC in England. Cancer was diagnosed in 7% of patients and serious non-cancer conditions in 36%—justifying the RDC approach in vague symptom patients.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference42 articles.
1. Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Niksic, M. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018). 2. De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 15, 23–34 (2014). 3. Abdel-Rahman, M., Stockton, D., Rachet, B., Hakulinen, T. & Coleman, M. P. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br. J. Cancer 101, S115–S124 (2009). 4. Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C. et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127–138 (2011). 5. Pedersen, A. F., Forbes, L., Brain, K., Hvidberg, L., Wulff, C. N., Lagerlund, M. et al. Negative cancer beliefs, recognition of cancer symptoms and anticipated time to help-seeking: an international cancer benchmarking partnership (ICBP) study. BMC Cancer 18, 363 (2018).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|